Cannabis Law Report

OCTOBER 1, 2021

Virpax is developing branded, non-addictive pain management and neurological product candidates using its proprietary technologies to optimize and target drug delivery. Epoladerm™ is a topical diclofenac metered-dose spray film formulation being developed to manage acute musculoskeletal pain and osteoarthritis.

Research and Development 52

Research and Development Pharmaceutical Clinical Trials Chronic Pain 52

TheAnswerPage

JANUARY 11, 2022

As reviewed in a recent Forbes article, “a study of more than 400 health care professionals has revealed that most physicians lack knowledge of medicinal cannabis, with 65% saying that they have been asked about medical marijuana as a treatment for chronic pain but were unable to answer their patients’ questions” (1).

Patients 98

Patients Education Marijuana Therapy 98

Puff Puff Post

SEPTEMBER 16, 2019

“A significant issue preventing the consideration of cannabinoid medicine by healthcare professionals is that the topic is not typically included in the medical school curriculum,” comments Dr. Mark Ware, Chief Medical Officer, Canopy Growth. Event details below: Date: Tuesday, September 17th 2019. Time: 9:00AM to 5:00PM.

Programs 40

Programs Research and Development Education Treatment 40

Cannabis Law Report

MARCH 19, 2020

2 At the conclusion of the meeting, FDA stated that it would form an internal working group to study data gaps relating to CBD. As indicated by FDA’s recent announcement, the collection of data about the risks and benefits of CBD remains a priority for the agency. FDA submitted this report last week, as is discussed below.

CBD 45

CBD Research and Development Seed-To-Sale Data 45

Cannabis Law Report

NOVEMBER 15, 2021

Our lead product candidate is Envelta™, which utilizes MET to deliver enkephalin nanoparticles for acute and chronic pain including pain associated with cancer. Epoladerm™ is a topical diclofenac spray film formulation being developed to manage osteoarthritis pain. TABLES FOLLOW.

Pharmaceutical 52

Pharmaceutical Research and Development Clinical Trials Chronic Pain 52

Cannabis Law Report

MAY 6, 2022

Examples of sellers’ language the FDA views as illegal are the following: “Our line of …CBD oil … is great for insomnia, epilepsy, MS, schizophrenia, and chronic pain.”. Pre-clinical data support the possible use of CBD with Panic Disorder…Bipolar Disorder.”. Taking CBD can relieve pain.”. Donovan or Leslie Bender.

THC 52

THC CBD Media Food 52

Cannabis Law Report

NOVEMBER 24, 2021

At the same time, the outlook on cannabis research data is largely positive. Chronic pain or pain were the conditions most frequently mentioned in articles about cannabis, followed by epilepsy, cancer or cancer pain, and nausea and chemotherapy. Data collection.

Research and Development 52

Research and Development Medicine Access Media 52

Cannabis Law Report

OCTOBER 17, 2019

Retailers such as Walgreens, CVS, Rite Aid, Kroger, Safeway, Nordstrom, and DSW are selling or plan to sell CBD-infused topical lotions, cosmetics, and even edibles where they are legally able to do so. Another researcher, New Frontier Data, pegged the global value of legal and illicit cannabis together at $340 billion in 2018.

Law 40

Law Seed-To-Sale Hemp Recreational 40